Chemical strategies for development of ATR inhibitors

Expert Reviews in Molecular Medicine

Volumn 16, Issue , 2014, Pages

  Llona Minguez, Sabin ^a   Höglund, Andreas ^a   Jacques, Sylvain A ^a   Koolmeister, Tobias ^a   Helleday, Thomas ^a  

^a SCIENCE FOR LIFE LABORATORY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ALSTERPAULLONE; ANTINEOPLASTIC AGENT; ATR PROTEIN; ATR PROTEIN INHIBITOR; CARBOPLATIN; CISPLATIN; CURCUMIN; DACTOLISIB; DOXORUBICIN; GEMCITABINE; PHOSPHOTRANSFERASE INHIBITOR; SELUMETINIB; SULFONIMIDE DERIVATIVE; UNCLASSIFIED DRUG; VX 970; ATM PROTEIN; ATR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

DNA CROSS LINKING; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DRUG INDUSTRY; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IC50; MALIGNANT NEOPLASM; NONHUMAN; ONCOLOGY; PANCREAS CANCER; PHARMACOLOGICAL PROCEDURES; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG DEVELOPMENT; ENZYMOLOGY; GENETICS; IC 50; METABOLISM; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; DNA DAMAGE; DNA REPAIR; DRUG DISCOVERY; HUMANS; INHIBITORY CONCENTRATION 50; NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 84906929921     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/erm.2014.10     Document Type: Review

References (81)

1. Hoeijmakers, J. H. (2009) DNA damage, aging, and cancer. New England Journal of Medicine 361, 1475-1485
2. Shiloh, Y. (2003) ATM and related protein kinases: safeguarding genome integrity. Nature Reviews Cancer 3, 155-168
3. Phillips, D. H. et al. (1988) Correlation of DNA adduct levels in human lung with cigarette smoking. Nature 336, 790-792
4. Lindahl, T. and Barnes, D. E. (2000) Repair of endogenous DNA damage. Cold Spring Harbor Symposia on Quantitative Biology 65, 127-134
5. Cortez, D. et al. (2001) ATR and ATRIP: partners in checkpoint signaling. Science 294, 1713-1716
6. Zou, L. and Elledge, S. J. (2003) Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 300, 1542-1548
7. Delacroix, S. et al. (2007) The Rad9-Hus1-Rad1 (9-1-1) clamp activates checkpoint signaling via TopBP1. Genes, Development 21, 1472-1477
8. Lee, J., Kumagai, A. and Dunphy, W. G. (2007) The Rad9-Hus1-Rad1 checkpoint clamp regulates interaction of TopBP1 withATR. Journal of Biological Chemistry 282, 28036-28044
9. Mordes, D. A. et al. (2008) TopBP1 activates ATR through ATRIP and a PIKK regulatory domain. Genes, Development 22, 1478-1489
10. Kondo, T. et al. (2001) Recruitment of Mec1 and Ddc1 checkpoint proteins to double-strand breaks through distinct mechanisms. Science 294, 867-870
11. Melo, J. A., Cohen, J. and Toczyski, D. P. (2001) Two checkpoint complexes are independently recruited to sites of DNA damage in vivo. Genes, Development 15, 2809-2821
12. Matsuoka, S. et al. (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160-1166
13. Tibbetts, R. S. et al. (1999) A role for ATR in the DNA damage-induced phosphorylation of p53. Genes, Development 13, 152-157
14. Dumaz, N. and Meek, D. W. (1999) Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO Journal 18, 7002-7010
15. López-Contreras, A. J. and Fernandez-Capetillo, O. (2010) The ATR barrier to replication-born DNA damage. DNA Repair 9, 1249-1255
16. Fokas, E. et al. (2013) TargetingATR inDNAdamage response and cancer therapeutics. Cancer Treatment Reviews 40, 109-117
17. Nghiem, P. et al. (2001) ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. Proceedings of the National Academy of Sciences USA 98, 9092-9097
18. Dai, Y. and Grant, S. (2010) New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clinical Cancer Research 16, 376-383
19. Garrett, M. D. and Collins, I. (2011) Anticancer therapy with checkpoint inhibitors: what, where and when Trends in Pharmacological Sciences 32, 308-316
20. Chen, C. et al. (2009) CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors. Molecular Cancer 8, 1-16
21. Höglund, A. et al. (2011) Therapeutic implications for the induced levels of CHK1 in MYC-expressing cancer cells. Clinical Cancer Research 17, 7067-7079
22. Cole, K. A. et al. (2011) RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proceedings of the National Academy of Sciences USA 108, 3336-3341
23. Schoppy, D. W. et al. (2012) Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. The Journal of Clinical Investigation 122, 241-252
24. http://clinicaltrials. gov/ct2/show/NCT01955668
25. https://www. clinicaltrialsregister. eu/ctr-search/trial/2012-003126-25/GB
26. Vlahos, C. J. et al. (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). Journal of Biological Chemistry 269, 5241-5248
27. Rosenzweig, K. E. et al. (1997) Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clinical Cancer Research 3, 1149-1156
28. Lee, C. M. et al. (2006) Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. Clinical Cancer Research 12, 250-256
29. Knight, Z. A. et al. (2006) A pharmacological map of the PI3-K family defines a role for p110 in insulin signaling. Cell 125, 733-747
30. Sarkaria, J. N. et al. (1998) Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Research 58, 4375-4382
31. Sarkaria, J. N. et al. (1999) Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, Caffeine. Cancer Research 59, 4375-4382
32. Planelles, V., Roshal, M. and Zhu, Y. H. (2003) Patent WO2003068929A2, University of Rochester, USA; University of Utah
33. Nghiem, P. and Fujii, S. (2005) Patent US20050276765A1, General Hospital Corporation, USA
34. Nishida, H., Hamamori, Y. and Konishi, T. (2007) Patent WO2007046426A1, Niigata Tlo Corp., Japan
35. Nishida, H. et al. (2009) Inhibition ofATRprotein kinase activity by schisandrin B in DNA damage response. Nucleic Acids Research 37, 5678-5689
36. Liu, Q. et al. (2013) Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, andATR. Cancer Research 73, 2574-2586
37. Toledo, L. I. et al. (2011)Acell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nature Structural, Molecular Biology 18, 721-727
38. Kumagai, A. et al. (2006) TopBP1 activates the ATR-ATRIP complex. Cell 124, 943-955
39. Toledo, L. I. et al. (2008) ATR signaling can drive cells into senescence in the absence ofDNAbreaks. Genes, Development 22, 297-302
40. http://www. merckmillipore. com/life-scienceresearch/ucn-01/EMD-BIO-539644/p-R66b. s1LTrMAAAEWx2EfVhTm
41. Maira, S.-M. et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Molecular Cancer Therapeutics 7, 1851-1863
42. http://clinicaltrials. gov/show/NCT00620594
43. Konstantinidou, G. et al. (2009) Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Research 69, 7644-7652
44. Gilad, O. et al. (2010) Combining ATR suppression with oncogenic ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Research 70, 9693-9702
45. Peasland, A. et al. (2011) Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. British Journal of Cancer 105, 372-381
46. D'Andrea, A. D. and Taniguchi, T. (2006) Patent WO2006127978A2, Dana Farber Cancer Institute Inc., USA
47. Andreassen, P. R., D'Andrea, A. D. and Taniguchi, T. (2004)ATR couples FANCD2monoubiquitination to the DNA-damage response. Genes, Development 18, 1958-1963
48. Ho, G. P. H. et al. (2006) Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance. Molecular and Cellular Biology 26, 7005-7015
49. Kim, T. K., Won, J.-J. and Yi, Y.-W. (2007) Patent WO2007015632A1, Cgk Co., Ltd., S. Korea
50. Won, J. et al. (2006) Small molecule-based reversible reprogramming of cellular lifespan. Nature Chemical Biology 2, 369-374
51. Won, J. et al. (2008) Retraction: small molecule-based reversible reprogramming of cellular lifespan. Nature Chemical Biology 4, 431-431
52. Foote, K. M. and Nissink, J. W. M. (2010) Patent WO2010073034A1, Astrazeneca AB, Swed. ; Astrazeneca UK Limited
53. Foote, K. M., Nissink, J. W. M. and Turner, P. (2011) Patent WO2011154737A1, AstraZeneca AB, Swed. ; AstraZeneca UK Limited
54. Charrier, J.-D. et al. (2010) Patent WO2010054398A1, Vertex Pharmaceuticals Incorporated, USA
55. Charrier, J.-D. et al. (2011) Patent WO2011143426A1, Vertex Pharmaceuticals Incorporated, USA
56. Charrier, J.-D. et al. (2010) Patent WO2010071837A1, Vertex Pharmaceuticals Incorporated, USA
57. Charrier, J.-D., Durrant, S. J. and Knegtel, R. (2013) Patent WO2013071085A1, Vertex Pharmaceuticals Incorporated, USA
58. Charrier, J.-D. et al. (2011) Patent WO2011143419A1, Vertex Pharmaceuticals Incorporated, USA
59. Charrier, J.-D. et al. (2011) Patent WO2011143399A1, Vertex Pharmaceuticals Incorporated, USA
60. Charrier, J.-D. et al. (2011) Patent WO2011143422A1, Vertex Pharmaceuticals Incorporated, USA
61. Charrier, J.-D. et al. (2011) PatentWO2011143425A2, Vertex Pharmaceuticals Incorporated, USA
62. Charrier, J.-D., Durrant, S. J. and Shaw, D. M. (2013) Patent WO2013071088A1, Vertex Pharmaceuticals Incorporated, USA
63. Charrier, J.-D. et al. (2011) PatentWO2011143423A2, Vertex Pharmaceuticals Incorporated, USA
64. Charrier, J.-D. and Kay, D. (2013) Patent WO2013071094A1, Vertex Pharmaceuticals Incorporated, USA
65. Charrier, J.-D. et al. (2012) PatentWO2012138938A1, Vertex Pharmaceuticals Incorporated, USA
66. Charrier, J.-D. et al. (2011) PatentWO2011163527A1, Vertex Pharmaceuticals Incorporated, USA
67. Charrier, J.-D. et al. (2013) PatentWO2013071090A1, Vertex Pharmaceuticals Incorporated, USA
68. Charrier, J.-D. et al. (2013) PatentWO2013049726A2, Vertex Pharmaceuticals Incorporated, USA
69. Charrier, J.-D. et al. (2013) PatentWO2013049719A1, Vertex Pharmaceuticals Incorporated, USA
70. Everitt, S. et al. (2012) Patent WO2012178124A1, Vertex Pharmaceuticals Incorporated, USA
71. MacCormick, S. etal. (2012)PatentWO2012178123A1, Vertex Pharmaceuticals Incorporated, USA 72
72. Pollard J. R., Reaper P. M. (2013)Patent WO2013049859A1, Vertex Pharmaceuticals Incorporated, USA
73. Storck, P.-H. et al. (2012) Patent WO2012178125A1, Vertex Pharmaceuticals Incorporated, USA
74. Foote, K. M. et al. (2013) Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl) cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. Journal of Medicinal Chemistry 56, 2125-2138
75. Reaper, P. M. et al. (2011) Selective killing of ATM-or p53-deficient cancer cells through inhibition of ATR. Nature Chemical Biology 7, 428-430
76. Charrier, J.-D. et al. (2011) Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. Journal of Medicinal Chemistry 54, 2320-2330
77. Cao, Y. F. et al. (2010) CYP3A catalyses schizandrin biotransformation in human, minipig and rat liver microsomes. Xenobiotica 40, 38-47
78. Morphy, R. (2009) Selectively nonselective kinase inhibition: striking the right balance. Journal of Medicinal Chemistry 53, 1413-1437
79. Knight, Z. A., Lin, H. and Shokat, K. M. (2010)Targeting the cancer kinome through polypharmacology. Nature Reviews Cancer 10, 130-137
80. Dar, A. C. et al. (2012) Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature 486, 80-84
81. Wagner, J. M. and Kaufmann, S. H. (2010) Prospects for the use of ATR inhibitors to treat cancer. Pharmaceuticals 3, 1311-1334